ArticleNeoplasia (New York, N.Y.)2026
STAT5A-RNF8 signaling regulates homologous recombination repair and cisplatin responsiveness in cervical cancer.
Article in Neoplasia (New York, N.Y.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cisplatin resistance remains a major limitation in the treatment of cervical cancer, with enhanced DNA damage repair contributing to reduced therapeutic sensitivity. The role of STAT5A in coordinating DNA double-strand break repair under therapeutic stress remains unclear. Here, we investigated the role of STAT5A in cisplatin responsiveness using clinical tissue analysis, CRISPR/Cas9-based genetic models, DNA repair assays, and xenograft models. STAT5A depletion sensitized cervical cancer cells to cisplatin, whereas STAT5A overexpression reduced cisplatin sensitivity. Mechanistically, STAT5A showed increased spatial association with γH2AX-positive nuclear regions following cisplatin exposure and transcriptionally promoted RNF8 expression. STAT5A enhanced HR-associated repair through an RNF8-mediated mechanism, as supported by reciprocal genetic experiments and residual DNA damage analysis. STAT5A loss was accompanied by reduced ATM/CHK2 activation, decreased expression of MRN complex components, RNF8 and RAD51, and increased persistence of cisplatin-associated DNA damage. Importantly, pharmacological inhibition of STAT5 reduced RNF8 expression, increased DNA damage, and enhanced the antitumor activity of cisplatin in cellular and xenograft models. Together, these findings identify STAT5A-RNF8 signaling as a regulator of HR-associated DNA repair and cisplatin responsiveness in cervical cancer and support further evaluation of this pathway as a therapeutic target.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.